abstract |
The present invention relates to the use ofninhibitors of the expressed proteins of TCF target genesnwhose expression is regulated by TCF/β-catenin complexesnfor the preparation of a therapeutical composition for thentreatment of cancers in which TCF/β-catenin signaling isnderegulated. Such inhibitors can be antibodies, smallnmolecules, antisense RNA and dsRNA for use in RNAi. Theninvention also relates to these inhibitors per se . |